Pediatric heart transplant waiting lists carry mortality rates approaching 25%, yet donation protocols have historically excluded hearts from donors who die from cardiac arrest rather than brain death. This exclusion has limited the already scarce pool of pediatric donor hearts, leaving children with advanced heart failure fewer lifesaving options than adults.
Researchers in the UK and Belgium have now demonstrated that hypothermic oxygenated perfusion (HOPE) technology can successfully preserve and transplant hearts from pediatric donors after circulatory death, previously considered unsuitable for transplantation. The technique involves cooling donor hearts to 4-8°C while continuously perfusing them with oxygenated solution. In their clinical series, six hearts from donors aged 16 months to 13 years were successfully transplanted, including three from donation after circulatory death with donors as small as 9 kg. All recipients showed 100% survival at median follow-up of 287 days with normal heart function.
This breakthrough addresses a critical disparity in transplant medicine. While donation after circulatory death has significantly expanded adult heart transplant programs globally, pediatric programs have lacked the specialized equipment and protocols needed for smaller hearts. The successful adaptation of HOPE technology to pediatric cases required developing miniaturized perfusion cannulas and modified surgical techniques including aortic arch reconstruction. The 19-minute median warm ischemic time achieved suggests the technique can maintain heart viability even after circulatory arrest. This advance could potentially expand the pediatric donor pool by 30-50%, offering hope to families facing one of medicine's most heartbreaking shortages.